SPARC entered into a licensing agreement with Biomodifying

Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target.

Biomodifying, LLC is a biotech company dedicated to identifying and exploiting molecules overexpressed by cancer cells by developing therapies that specifically target tumors while sparing normal, non-cancerous tissues – an approach that is expected to contribute to the development of therapies less harsh and more adapted to larger patient populations than currently used chemotherapy regimens.

Under the agreement, Biomodifying is eligible for an up-front payment, milestone payments on pre-specified clinical, regulatory, and commercial milestones, as well as royalties on sales. In addition, SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP.